Skip to main content

Achieve Life Sciences, Inc.

corporate_fare Company Profile

Achieve Life Sciences, Inc.

ACHV·NASDAQ·Life Sciences·CIK 0000949858

We are a late-stage clinical specialty pharmaceutical company focused on developing and selling cytisinicline to address the global nicotine dependence epidemic. In the United States, an estimated 29 million adults smoke combustible cigarettes and 17 million adults use e-cigarettes. Tobacco use causes over eight million deaths worldwide and nearly half a million deaths in the United States annually. Over 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are linked to smoking and secondhand smoke. While e-cigarettes are considered less harmful than combustible cigarettes, they are highly addictive and can deliver harmful chemicals. In 2024, 1.6 million high school and middle school students reported using e-cigarettes, and research indicates adolescents who have used e-cigarettes are seven times more likely to become smokers one year later. In 2024, the FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette, or vaping, cessation. This designation expedites the development and review of new drugs for serious or life-threatening conditions with evidence of substantial improvement over existing therapies. In October 2025, the FDA awarded cytisinicline for nicotine e-cigarette, or vaping, cessation the Commissioner's National Priority Voucher (CNPV) as part of a pilot program. A CNPV is given to product candidates with significant potential to address a major national priority, such as a large unmet medical need, reducing healthcare utilization, or addressing a public health crisis.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACHV at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Achieve Life Sciences Secures Key FDA PDUFA Date, National Priority Voucher for Cytisinicline
  • Achieve Life Sciences Files $300M Universal Shelf Registration for Future Capital Raises

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$54.65M
Diluted EPS
-$1.25
Op. Cash Flow
-$49.47M
Free Cash Flow
-$49.47M
Cash & Equivalents
$20.93M
Total Debt
$11.19M
Debt / Equity
0.52×
Shares Outstanding
53.23M sh
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-197402
$5.48 -6.64% today
52-week range · as of 2026-11-10 $2.62 – $8.64
Market cap
$571.62M
Volume
1.9M (1.4× avg)
3-mo avg 1.3M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACHV - Filings & News (Page 2)

ACHV
Mar 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.12
Real-time Price: $5.48 info
Change: +$1.36 (+33%) info
Market Cap: $571.621M info
ACHV
Jan 23, 2026, 4:04 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $5.60
Real-time Price: $5.48 info
Change: -$0.120 (-2%) info
Market Cap: $571.621M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets